← All workstreams
Medical psychedelics

The Feilding Commission

Psilocybin remains in Schedule 1 without justification in the evidence, blocking research and patient access. We work to change that — safely, ethically and equitably.

What we believe

The Schedule 1 status of psilocybin, and other promising substances such as MDMA, poses serious barriers to research and blocks patient access in the UK — with no justification in the evidence.

Psychedelic-assisted therapy holds real promise for mental health and for the UK life-sciences industry. Its rollout must be guided by a safe, ethical and equitable framework.

What we've done

SEPT 2025

Charlotte Nichols MP launched the Feilding Commission — an independent body developing a UK framework for psychedelic-assisted therapy, named in honour of the late Amanda Feilding.

2023

Secured the first-ever parliamentary debates on psilocybin — an adjournment debate (14 March) and a back-bench business debate (18 May) supported by 26 cross-party MPs.

ONGOING

Established the Psilocybin Access Rights (#PAR) campaign, gained the support of the Royal College of Psychiatrists, and prompted the ACMD's review of barriers to research.